Michal A. Elovitz

Michal A. Elovitz

Auto-generated profile, based on publicly available information

Michal A. Elovitz

Women’s Biomedical Research Institute, Department of Obstetrics, Gynecology, and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2016 in Microbiome
Verified
Journal Article
Open access
PDF file
ALAbigail P. Lauder
Abigail P. Lauder
ARAoife M. Roche
Aoife M. Roche
SSScott Sherrill-Mix
Scott Sherrill-Mix
ABAubrey Bailey
Aubrey Bailey
ALAlice L. Laughlin
Alice L. Laughlin
FBFrederic D. Bushman
Frederic D. Bushman
Recent studies have suggested that bacteria associated with the placenta—a “placental microbiome”—may be important in reproductive health and disease. However, a challenge in working with specimens with low bacterial biomass, such as placental samples, is that some or all of the bacterial DNA may derive from contamination in dust or commercial reagents. To investigate this, we compared placental samples from healthy deliveries to a matched set of contamination controls, as well as to oral and vaginal samples from the same women. We quantified total 16S rRNA gene copies using quantitative PCR and found that placental samples and negative controls contained low and indistinguishable copy numbers. Oral and vaginal swab samples, in contrast, showed higher copy numbers. We carried out 16S rRNA gene sequencing and community analysis and found no separation between communities from placental samples and contamination controls, though oral and vaginal samples showed characteristic, distinctive composition. Two different DNA purification methods were compared with similar conclusions, though the composition of the contamination background differed. Authentically present microbiota should yield mostly similar results regardless of the purification method used—this was seen for oral samples, but no placental bacterial lineages were (1) shared between extraction methods, (2) present at >1 % of the total, and (3) present at greater abundance in placental samples than contamination controls. We conclude that for this sample set, using the methods described, we could not distinguish between placental samples and contamination introduced during DNA purification.

25 January 2023 in Nature
Verified
Journal Article
Closed access
PDF file
KKKatherine M. Kennedy
Katherine M. Kennedy
MGMarcus C. De Goffau
Marcus C. De Goffau
MPMaria Elisa Perez-Muñoz
Maria Elisa Perez-Muñoz
MAMarie-Claire Arrieta
Marie-Claire Arrieta
FBFredrik Bäckhed
Fredrik Bäckhed
JWJens Walter
Jens Walter

21 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MEMichal A. Elovitz
Michal A. Elovitz
PGPawel Gajer
Pawel Gajer
VRValerie Riis
Valerie Riis
ABAmy G. Brown
Amy G. Brown
MHMichael S. Humphrys
Michael S. Humphrys
JRJacques Ravel
Jacques Ravel
Failure to predict and understand the causes of preterm birth, the leading cause of neonatal morbidity and mortality, have limited effective interventions and therapeutics. From a cohort of 2000 pregnant women, we performed a nested case control study on 107 well-phenotyped cases of spontaneous preterm birth (sPTB) and 432 women delivering at term. Using innovative Bayesian modeling of cervicovaginal microbiota, seven bacterial taxa were significantly associated with increased risk of sPTB, with a stronger effect in African American women. However, higher vaginal levels of β-defensin-2 lowered the risk of sPTB associated with cervicovaginal microbiota in an ethnicity-dependent manner. Surprisingly, even in Lactobacillus spp. dominated cervicovaginal microbiota, low β-defensin-2 was associated with increased risk of sPTB. These findings hold promise for diagnostics to accurately identify women at risk for sPTB early in pregnancy. Therapeutic strategies could include immune modulators and microbiome-based therapeutics to reduce this significant health burden.

1 November 2003 in The American Journal of Pathology
Verified
Journal Article
Closed access
MEMichal A. Elovitz
Michal A. Elovitz
ZWZhao Wang
Zhao Wang
ECEdward K. Chien
Edward K. Chien
DRDaniel F. Rychlik
Daniel F. Rychlik
MPMark Phillippe
Mark Phillippe

1 April 2015 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
DHDavid M. Haas
David M. Haas
CPCorette B. Parker
Corette B. Parker
DWDeborah A. Wing
Deborah A. Wing
SPSamuel Parry
Samuel Parry
WGWilliam A. Grobman
William A. Grobman
URUma M. Reddy
Uma M. Reddy
The primary aim of the "Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be" is to determine maternal characteristics, which include genetic, physiologic response to pregnancy, and environmental factors that predict adverse pregnancy outcomes. Nulliparous women in the first trimester of pregnancy were recruited into an observational cohort study. Participants were seen at 3 study visits during pregnancy and again at delivery. We collected data from in-clinic interviews, take-home surveys, clinical measurements, ultrasound studies, and chart abstractions. Maternal biospecimens (serum, plasma, urine, cervicovaginal fluid) at antepartum study visits and delivery specimens (placenta, umbilical cord, cord blood) were collected, processed, and stored. The primary outcome of the study was defined as pregnancy ending at <37+0 weeks' gestation. Key study hypotheses involve adverse pregnancy outcomes of spontaneous preterm birth, preeclampsia, and fetal growth restriction. We recruited 10,037 women to the study. Basic characteristics of the cohort at screening are reported. The "Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be" cohort study methods and procedures can help investigators when they plan future projects.

1 December 2004 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
MEMichal A. Elovitz
Michal A. Elovitz
CMConjeevaram Mrinalini
Conjeevaram Mrinalini